This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Thomas Laetz, PhD; George Silberman, MA

JAMA. 1991;266(21):2996-2999.

Abstract
Objective.
—To determine the prevalence of off-label anticancer drug use (ie, using drugs to treat conditions other than those listed on the Food and Drug Administration's approved drug label), the extent of reimbursement denials for these uses, and the effect of denials on the treatment of cancer patients.

Design, Setting, and Participants.
—A three-part questionnaire was sent to a randomized sample of oncologists taken from the 1990 membership of the American Society of Clinical Oncology in March 1990. A response rate of 56% yielded information from 681 oncologists on the drugs they prescribed to 2018 new cancer patients and on those they frequently use in treating 11 specific types of cancer.

Main Outcome Measures.
—The labeled uses of the drugs prescribed and frequently used in chemotherapies were checked against the indications treated to determine whether they were prescribed for off-label uses. Three drug compendia were used as cited sources of off-label drug uses. The extent of reimbursement denials over the last 12 months and their effects on treatments were based on respondent opinions.

Main Results.
—Off-label drug use is prevalent and dominates the chemotherapy regimens of cancers that are more difficult to treat and for which there are no cures or agreements on standardized treatment. Most oncologists reported frustration with shifting reimbursement policies in general and with an increasing rate of denials for some off-label drug uses. Indeed, a surprising number of oncologists claimed that these policies caused them to alter preferred treatments and site of care.

Conclusion.
—These findings suggest the need for public discussion of off-label drug use issues so that appropriate policies can be developed.

(JAMA. 1991;266:2996-2999)

Author Affiliations
From the US General Accounting Office, Washington, DC.

Footnotes
Reprint requests to PEMD/GAO, 441 G St NW, Washington, DC 20548 (Mr Silberman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost of Cancer Care: Issues and Implications
Meropol and Schulman
JCO 2007;25:180-186.
ABSTRACT | FULL TEXT  

Rethinking Risk-Benefit Assessment for Phase I Cancer Trials
Joffe and Miller
JCO 2006;24:2987-2990.
FULL TEXT  

The Phase III Trial in the Era of Targeted Therapy: Unraveling the "Go or No Go" Decision
Roberts et al.
JCO 2003;21:3683-3695.
ABSTRACT | FULL TEXT  

Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children
Conroy et al.
Ann Oncol 2003;14:42-47.
ABSTRACT | FULL TEXT  

Varieties of Healing. 2: A Taxonomy of Unconventional Healing Practices
Kaptchuk and Eisenberg
ANN INTERN MED 2001;135:196-204.
ABSTRACT | FULL TEXT  

Homeopathy--The Emperor's Medicine-Reply
Kaptchuk and Ernst
Arch Intern Med 1997;157:1140-1140.
ABSTRACT  

Conflicting Aims: Voluntary Health Insurance and Contemporary Medical Practice
Siu
Arch Intern Med 1993;153:457-463.
ABSTRACT  

Off-Label Uses of Anticancer Drugs
Abeloff
JAMA 1992;267:2473-2474.
ABSTRACT